Skip to main content
NEUROTECH INTERNATIONAL LIMITED logo

NEUROTECH INTERNATIONAL LIMITED — Investor Relations & Filings

Ticker · NTI ISIN · AU000000NTI9 ASX Professional, scientific and technical activities
Open in API
Filings indexed 667 across all filing types
Latest filing 2025-02-23 Director's Dealing
Country AU Australia
Listing ASX NTI

About NEUROTECH INTERNATIONAL LIMITED

https://neurotechinternational.com/

Neurotech International Limited is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapeutics for neurodevelopmental and neurological disorders. The company specializes in neuroprotective therapies, primarily targeting pediatric conditions with significant unmet medical needs, including Autism Spectrum Disorder (ASD), Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS), and Pediatric Acute-onset Neuropsychiatric Syndrome (PANS). Its lead drug candidate, NTI164, is a proprietary, broad-spectrum cannabinoid formulation derived from a unique cannabis strain. NTI164 is engineered to exert anti-inflammatory and neuroprotective effects by modulating neuroinflammatory pathways. The company conducts clinical trials to establish the safety and efficacy of its treatments, aiming to provide transformative behavioral and functional improvements for patients.

Recent filings

Filing Released Lang Actions
Change of Director's Interest Notice 2 pages 162.0KB
Director's Dealing Classification · 100% confidence The document is titled 'Appendix 3Y Change of Director’s Interest Notice' and references ASX listing rule 3.19A.2 and section 205G of the Corporations Act. It details changes in securities holdings by a company director, including the number and class of securities acquired, disposed, and held before and after the change. The document is a formal notification of insider share transactions by a director, which aligns with the definition of Director's Dealing filings. The document length is 3673 characters, which is consistent with a detailed notice rather than a brief announcement or a full report. There is no financial performance data or management discussion, so it is not an Annual Report or Interim Report. It is not a regulatory filing or announcement of a report but a specific insider transaction report.
2025-02-23 English
NTI Signs Development Agreement for Cannabinoid Therapies 2 pages 135.3KB
Capital/Financing Update Classification · 95% confidence The document is an ASX announcement dated 13 February 2025, describing a new development agreement between Neurotech International Limited and RH Farma Dooel Skopje, a subsidiary of European Cannabis Company. The content focuses on the signing of a partnership agreement for pharmaceutical development of cannabinoid therapies, including details about the agreement terms, company backgrounds, and strategic goals. There are no financial statements, earnings data, or regulatory filings such as annual or interim reports. The document is a corporate announcement about a new development agreement, which fits best under Capital/Financing Update (CAP) as it relates to a strategic partnership and development agreement impacting the company's business and potential capital deployment. It is not a report publication announcement or regulatory filing, and it does not fit other categories like M&A, earnings release, or management reports. The document length (6718 characters) and content confirm it is a substantive announcement rather than a brief notice or certification.
2025-02-12 English
Initial Director's Interest Notice 2 pages 141.9KB
Director's Dealing Classification · 95% confidence The document is titled 'Appendix 3X Initial Director’s Interest Notice' and references ASX listing rule 3.19A.1 and section 205G of the Corporations Act. It details the appointment of a new director and their relevant interests in securities and contracts, including options granted as part of remuneration. The content focuses on the director's personal share transactions and interests rather than financial results, management changes broadly, or other report types. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is 2870 characters, which is consistent with a notice rather than a full report. Therefore, the correct classification is DIRS with high confidence.
2025-02-03 English
Neurotech Receives $2.44 Million R&D Tax Incentive Refund 1
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 31 January 2025, reporting that Neurotech International Limited has received a $2.44 million R&D tax incentive refund for the financial year ended 30 June 2024. It includes a brief financial update on cash position and a statement from the Executive Director. The document is short (3161 characters) and primarily serves as a notification of receipt of a government tax incentive refund, not a detailed financial report or earnings release. It does not contain comprehensive financial statements or detailed analysis. It is an announcement related to financing (cash inflow from tax incentive) but not a capital raising or financing activity per se. It is not a full financial report, earnings release, or management discussion. Therefore, the best fitting category is Regulatory Filings (RNS), which covers general regulatory announcements and miscellaneous filings that do not fit other categories.
2025-01-30 English
Quarterly Activities/Appendix 4C Cash Flow Report 9 pages 380.8KB
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Quarterly Activities Report for the period ending 31 December 2024' and includes detailed clinical updates, regulatory progress, corporate activity, and financial commentary including cash flow and R&D expenses. It references the Appendix 4C Quarterly Cash Flow Report, which is a standard quarterly report for ASX-listed companies. The content includes substantive financial data and operational updates for the quarter, consistent with an Interim / Quarterly Report. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q2 2025
2025-01-28 English
Notice of Expiry of Listed Options 3 pages 158.8KB
Share Issue/Capital Change Classification · 95% confidence The document is an ASX announcement dated 17 December 2024 regarding the expiry of listed options (ASX: NTIOA) for Neurotech International Limited. It provides detailed information to option holders about the expiry date, exercise price, cessation of quotation on ASX, and instructions on exercising or selling the options. The content focuses on the capital instruments (options) and their expiry, which is a capital structure event. There is no financial report, earnings data, or management discussion. The document is not a report itself but an official announcement related to capital changes, specifically the expiry of listed options and cessation of their trading. Therefore, the most appropriate classification is Share Issue/Capital Change (SHA). The document length (6616 characters) and detailed content confirm it is not a mere brief notice or report publication announcement but a substantive capital update.
2024-12-16 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.